30 results
8-K
EX-99.1
RPHM
Reneo Pharmaceuticals Inc
13 Nov 23
Reneo Pharmaceuticals Reports Third Quarter 2023 Financial Results
4:00pm
in the STRIDE study or the mavodelpar Phase 1b study. The study is designed to evaluate the long-term safety and tolerability of 100 mg mavodelpar
8-K
EX-99.1
ihmx3w sir0p
11 May 23
Reneo Pharmaceuticals Reports First Quarter 2023 Financial Results
4:07pm
8-K
EX-10.1
2jvd jaqku64qv
5 May 23
Reneo Pharmaceuticals Announces Proposed Public Offering of Common Stock
4:33pm
8-K
EX-1.1
8gihz6ct7xuv 5m0
5 May 23
Reneo Pharmaceuticals Announces Proposed Public Offering of Common Stock
4:33pm
424B5
7olg0kdgjerb
4 May 23
Prospectus supplement for primary offering
5:15pm
424B5
9rnvgwhx
3 May 23
Prospectus supplement for primary offering
4:20pm
8-K
EX-99.1
29n mz0cpfs
8 Nov 22
Reneo Pharmaceuticals Reports Third Quarter 2022 Financial Results
4:16pm
8-K
EX-99.1
djtujogak4z 5n4w
9 Aug 22
Reneo Pharmaceuticals Reports Second Quarter 2022 Financial Results
12:00am
8-K
EX-99.1
43ywzx9v5u9jv
10 May 22
Reneo Pharmaceuticals Reports First Quarter 2022 Financial Results
4:09pm